Quantification of Striatal and Extrastriatal Dopamine Transporters with [18F]PR04.MZ and [18F] PI- 2620 PET in Patients with Progressive Supranuclear Palsy.
Objective: We aim to evaluate the differences in striatal subregional dopamine transporter loss between Parkinson disease (PD) and progressive supranuclear palsy (PSP) of any stage…18F-Florzolotau PET Imaging Captures the Distribution Patterns and Regional Vulnerability of Tau Pathology in Progressive Supranuclear Palsy
Objective: This study aimed to investigate whether 18F-Florzolotau PET imaging may capture the distribution patterns and regional vulnerability of tau pathology in PSP, and to…Brain FDG-PET-MRI for early diagnosis of corticobasal syndrome
Objective: To characterize brain fluorodeoxyglucose (FDG) PET-MRI findings in patients with corticobasal syndrome (CBS) and evaluate its utility in early diagnosis of Corticobasal Degeneration (CBD)…Identification of a Metabolic Brain Pattern Specific to Corticobasal Degeneration and Its Utility in Differential Diagnosis
Objective: To identify a metabolic brain pattern specific to corticobasal degeneration (CBD) and to develop a machine learning algorithm that can differentiate CBD from other…18F-Florzolotau PET imaging of tau pathology in the living brain of patients with corticobasal syndrome
Objective: To analyze the topographical patterns of tau pathology in the living brains of patients with CBS using 18F-Florzolotau PET imaging and to examine whether…Mesencephalic neuroglial cyst can produce clinical manifestations and a metabolic [18F] FDG PET pattern mimicking a Progressive Supranuclear Palsy Syndrome
Objective: To describe the clinical manifestations and structural and functional neuroimaging findings in a patient with a left mesencephalic neuroglial cyst, resembling a PSP. Background:…Clinical and radiological factors associated with mortality in Parkinson’s disease
Objective: To assess clinical and radiological risk factors of mortality in a cohort of patients with a clinical diagnosis of Parkinson’s disease (PD) according to…Combined approach in the diagnostic of Parkinson’s disease
Objective: Our aim was to develop and scientifically substantiate set of criteria for early(preclinical) diagnosis of neurodegenerative disorders with the assessment of a number of…6-[18F]fluoro-L-3,4-dihydroxyphenylalanine (F-DOPA) PET striatal binding patterns in patients with Parkinson’s Disease and Parkinson Plus Syndromes.
Objective: In this study we investigate striatal binding patterns in patients with Idiopathic Parkinson’s disease (IPD), compared to those with Parkinson Plus syndromes (PPS) versus…18f-PI-2620 tau PET neuroimaging, tau protein burden and 18f-PI-2620 tau autoradiography on human postmortem brain tissue in a PSP patient
Objective: Our aim is to describe the findings of 18F-PI-2620 tau-PET imaging, together with tau protein burden and 18F-PI-2620 tau autoradiography in brain tissue from…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 33
- Next Page »